David Cherney

561 total citations
28 papers, 378 citations indexed

About

David Cherney is a scholar working on Endocrinology, Diabetes and Metabolism, Pulmonary and Respiratory Medicine and Nephrology. According to data from OpenAlex, David Cherney has authored 28 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Endocrinology, Diabetes and Metabolism, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Nephrology. Recurrent topics in David Cherney's work include Diabetes Treatment and Management (17 papers), Chronic Kidney Disease and Diabetes (5 papers) and Gastric Cancer Management and Outcomes (5 papers). David Cherney is often cited by papers focused on Diabetes Treatment and Management (17 papers), Chronic Kidney Disease and Diabetes (5 papers) and Gastric Cancer Management and Outcomes (5 papers). David Cherney collaborates with scholars based in Canada, United States and United Kingdom. David Cherney's co-authors include Sharon E. Straus, Ayodele Odutayo, Michael Glogauer, J. W. Scholey, Siavash Hassanpour, Corneliu Sima, Noah Fine, Vathany Kulasingam, Katherine R. Tuttle and Hiddo J.L. Heerspink and has published in prestigious journals such as Circulation, Diabetes and Journal of the American Society of Nephrology.

In The Last Decade

David Cherney

26 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Cherney Canada 8 98 83 81 79 77 28 378
Jeffrey M. Curtis United States 11 37 0.4× 92 1.1× 56 0.7× 45 0.6× 199 2.6× 15 457
Paolo Monardo Italy 13 19 0.2× 37 0.4× 54 0.7× 230 2.9× 29 0.4× 31 439
Maki Yoshino Japan 10 14 0.1× 98 1.2× 40 0.5× 115 1.5× 150 1.9× 32 411
Angkawipa Trongtorsak United States 11 186 1.9× 21 0.3× 48 0.6× 18 0.2× 9 0.1× 54 323
Murat Akarsu Türkiye 9 58 0.6× 32 0.4× 107 1.3× 11 0.1× 3 0.0× 34 315
Ayelet Shauer Israel 11 308 3.1× 56 0.7× 81 1.0× 30 0.4× 2 0.0× 25 536
Vinod Kumar India 10 28 0.3× 19 0.2× 126 1.6× 6 0.1× 41 0.5× 82 350
Frances Harley Canada 10 50 0.5× 166 2.0× 165 2.0× 101 1.3× 2 0.0× 19 423
A Di Benedetto Italy 5 13 0.1× 30 0.4× 37 0.5× 56 0.7× 12 0.2× 9 211
Amal Al‐Eisa Kuwait 11 33 0.3× 33 0.4× 22 0.3× 111 1.4× 2 0.0× 22 318

Countries citing papers authored by David Cherney

Since Specialization
Citations

This map shows the geographic impact of David Cherney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Cherney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Cherney more than expected).

Fields of papers citing papers by David Cherney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Cherney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Cherney. The network helps show where David Cherney may publish in the future.

Co-authorship network of co-authors of David Cherney

This figure shows the co-authorship network connecting the top 25 collaborators of David Cherney. A scholar is included among the top collaborators of David Cherney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Cherney. David Cherney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heerspink, Hiddo J.L., Katherine R. Tuttle, Imre Pávó, et al.. (2024). Tirzepatide Reduces Albuminuria in Patients with T2D: Post-hoc Pooled Analysis of SURPASS 1-5. Diabetologie und Stoffwechsel. 19(S 01). S75–S75.
2.
Heerspink, Hiddo J.L., David Cherney, Abdul Halim Abdul Gafor, et al.. (2024). Effect of Avenciguat on Albuminuria in Patients with CKD. Journal of the American Society of Nephrology. 35(9). 1227–1239. 21 indexed citations
3.
Azhie, Amirhossein, Eunice Xiang‐Xuan Tan, Vikas S. Sridhar, et al.. (2024). Glucagon‐like peptide ‐1 receptor agonists and sodium‐glucose cotransporter ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients. Diabetes Obesity and Metabolism. 26(10). 4261–4272. 5 indexed citations
4.
Kosiborod, Mikhail, David Cherney, Kim A. Connelly, et al.. (2024). Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia. JACC Heart Failure. 12(10). 1707–1716. 6 indexed citations
5.
Heerspink, Hiddo J.L., Rajiv Agarwal, George L. Bakris, et al.. (2023). Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKD. Journal of the American Society of Nephrology. 34(11S). 678–678. 1 indexed citations
6.
Badrov, Mark B., Catherine F. Notarius, Elizabeth Keys, et al.. (2023). MUSCLE SYMPATHETIC EXCITATORY RESPONSES TO DYNAMIC ONE-LEG CYCLING EXERCISE ARE AUGMENTED IN HEART FAILURE WITH PRESERVED EJECTION FRACTION. Canadian Journal of Diabetes. 47(7). S44–S45. 1 indexed citations
7.
Tuttle, Katherine R., Stephen C. Bain, David Cherney, et al.. (2022). MO462: Change in KDIGO Kidney Risk Category With Semaglutide Treatment—A Post Hoc Analysis of the Sustain 6 Trial. Nephrology Dialysis Transplantation. 37(Supplement_3). 1 indexed citations
8.
9.
Bjornstad, Petter, David Cherney, Jack Lawson, et al.. (2022). MO399: Remodel: A Mechanistic Trial Evaluating the Effects of Semaglutide on the Kidneys In People With Type 2 Diabetes and Chronic Kidney Disease. Nephrology Dialysis Transplantation. 37(Supplement_3). 19 indexed citations
10.
11.
Pratley, Richard E., Samuel Dagogo‐Jack, B Charbonnel, et al.. (2021). 791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV. Diabetes. 70(Supplement_1). 3 indexed citations
12.
Cherney, David, Claire C. J. Dekkers, Sean Barbour, et al.. (2020). Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with Chronic Kidney Disease (DIAMOND): A Randomised Double Blind Cross-Over Trial. SSRN Electronic Journal. 2 indexed citations
13.
Heerspink, Hiddo J.L., Claire C. J. Dekkers, & David Cherney. (2020). Effects of the SGLT2 Inhibitor Dapagliflozin on Proteinuria in Non-Diabetic Patients with CKD (DIAMOND): A Randomized Double-Blind Cross-Over Trial. Journal of the American Society of Nephrology. 31(10S). 229–229. 1 indexed citations
14.
Tuttle, Katherine R., David Cherney, Samy Hadjadj, et al.. (2020). TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6. Nephrology Dialysis Transplantation. 35(Supplement_3). 1 indexed citations
15.
Kraus, Bettina J., Matthew R. Weir, George L. Bakris, et al.. (2020). LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’ IN EMPA-REG OUTCOME. Nephrology Dialysis Transplantation. 35(Supplement_3). 1 indexed citations
16.
17.
Kidokoro, Kengo, David Cherney, Vathany Kulasingam, et al.. (2018). Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging. Diabetes. 67(Supplement_1). 25 indexed citations
18.
Rajasekeran, Harindra, Yuliya Lytvyn, Michelle Hladunewich, et al.. (2016). The Effect of SGLT2 Inhibition on Urinary Adenosine Excretion in Patients with Type 1 Diabetes. Canadian Journal of Diabetes. 40(5). S64–S64. 3 indexed citations
19.
Odutayo, Ayodele & David Cherney. (2012). Cystatin C and acute changes in glomerular filtration rate. Clinical Nephrology. 78(7). 64–75. 38 indexed citations
20.
Cherney, David & Sharon E. Straus. (2002). Management of patients with hypertensive urgencies and emergencies. Journal of General Internal Medicine. 17(12). 937–945. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey M. Curtis Breakdown of academic impact, for papers by Paolo Monardo Breakdown of academic impact, for papers by Maki Yoshino Breakdown of academic impact, for papers by Angkawipa Trongtorsak Breakdown of academic impact, for papers by Murat Akarsu Breakdown of academic impact, for papers by Ayelet Shauer Breakdown of academic impact, for papers by Vinod Kumar Breakdown of academic impact, for papers by Frances Harley Breakdown of academic impact, for papers by A Di Benedetto Breakdown of academic impact, for papers by Amal Al‐Eisa
Rankless by CCL
2026